图为活动现场 光谷商学院揭牌仪式暨首期"卓越班"开班典礼13日在武汉东湖高新区(又称"中国光谷") 举行。该学院由武汉光谷人才集团实体化运营，未来3年计划培育超500名科技企业家与创业 者，推动不少于50家企业年营收突破亿元，并助力光谷瞪羚企业新增500家。 光谷商学院院长、华工科技产业股份有限公司董事长马新强表示，当前，许多科技创业 者能够攻克尖端技术，却往往在将成果转化为市场胜势时面临挑战，其核心在于从"技术逻 辑"到"商业逻辑"的认知跨越。中国光谷正加快迈向"世界光谷"，越来越多的光谷企业出海 全球，企业格局、资源整合、区域布局等都需要快速提升。他表示，学院的核心使命是成为 一个"赋能引擎"，通过精准实战的课程、无缝链接的产业生态以及价值共生的企业家社群， 系统培育具有全球格局的科技企业家。 图为活动现场 首期"卓越班"学员均来自省级以上专精特新企业、光谷瞪羚企业或已获知名投资机构注 资的企业，营收规模在1亿元至5亿元之间，处于规模化突破的关键阶段。课程由光谷商学院 与中欧国际工商学院等顶级学术伙伴共同设计，聚焦成长期企业的真实痛点，涵盖商业模式 创新、数字化经营、国际化战略等实战模块。师资阵容包括知名 ...

1月13日，光谷商学院正式揭牌成立，首期"卓越班"开班。学院计划在未来3年内，培育500名科技企业家与创业者，推动不少于50家企 业年营收突破亿元，并助力光谷瞪羚企业新增500家。 光谷商学院由光谷人才集团负责实体化运营，定位于培育"一批兼具技术基因、商业思维、全球视野的卓越科创企业家"。 "中国光谷"迈向"世界光谷"的新征程，呼唤世界一流的领军企业、世界一流的企业家。光谷商学院的诞生，旨在系统破解科技创业者 普遍面临的"长于技术、短于市场"的发展瓶颈，成为助推科技企业跨越成长鸿沟、攀登产业高峰的"赋能引擎"。 光谷商学院致力于培育一批引领光谷产业发展的领军人物。 光谷商学院师资力量雄厚，华工科技产业股份有限公司董事长马新强担任院长，蔚来集团董事长李斌、联影集团董事长薛敏、阅文集 团总裁侯晓楠、英诺赛科董事长骆薇薇、长江存储董事长陈南翔、长飞光纤总裁庄丹、乐福思董事长王学海、精测电子董事长彭骞、帝尔 激光董事长李志刚等企业家担任顾问委员会委员。 教授来自北大光华、清华五道口、中欧国际工商学院等顶尖商学院，武大经管学院、华科大管理学院、长城企业战略研究所、北京和 君商学、清控银杏、丰年资本、科锐国际等13家头部 ...

Group 1 - The brain-computer interface has significantly impacted the medical industry this year, with a medical device ETF attracting over 1 billion yuan in the last 10 days, indicating a surge in market interest [1] - Companies like Di'an Diagnostics and Yuyue Medical have seen stock increases of over 10% and 8% respectively, while the medical device ETF (159883) has risen over 3% [1] - Di'an Diagnostics highlighted that AI will drive rapid development in healthcare applications, particularly in primary care and health management, emphasizing the need for high-quality multimodal data [1] Group 2 - Multiple research institutions are optimistic about the medical device industry by 2026, with a focus on overseas market growth, high-value consumables procurement, and the profitability turning point for innovative devices [2] - The overseas market, especially in Europe and the US, is expected to be a major growth driver, with significant growth anticipated in high-value consumables such as orthopedics, electrophysiology, and surgical robots [2] - The application of AI in healthcare is accelerating, supported by national policies, with a clear trend towards commercialization and revenue growth in AI medical applications [2] Group 3 - The Hong Kong medical ETF (159366) is strategically positioned to benefit from AI in healthcare, with a high concentration of CROs and being the largest ETF in its category, offering good liquidity and T+0 support [3] - This ETF focuses on leading companies in the Hong Kong medical sector, allowing investors to share in the growth dividends of these enterprises [3]

1月14日，A股早盘反弹，三大股指集体上涨，创业板涨超1%，AI应用板块再度爆发，算力、存储板块活跃。港股早 盘亦走高，恒指、恒科指双双上涨，科网股分化，医药、有色金属走强。债市方面，国债期货调整。商品方面，金 属期货再度拉升，沪银涨近8%，铂金、钯金等涨幅居前。核心市场走势： | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | m/ | 4176.33 | 37.57 | 0.91% | | 399001 | 深证成指 | mal | 14402.23 | 232.83 | 1.64% | | 399006 | 创业板指 | 7 | 3380.63 | 58.74 | 1.77% | | 000300 | 沪深300 | Mal | 4806.26 | 45.23 | 0.95% | | 000016 | FiFF50 | that | 3164.20 | 31.27 | 1.00% | | 000680 | 科创综指 | mil | 1858.62 | 52.60 | 2.91% ...

Core Insights - The establishment of the Guanggu Business School aims to empower technology companies to overcome growth bottlenecks by focusing on "cognitive transformation" and "team enhancement" [1] - The school is led by Ma Xinqiang, Chairman of Huagong Technology, and has a strong advisory committee comprising leaders from various industries, including new energy vehicles and biomedicine [1] - The school’s mission is to serve as an "empowerment engine" for cultivating globally-minded technology entrepreneurs through practical courses and a connected industrial ecosystem [1] Summary by Sections School Structure and Objectives - Guanggu Business School is positioned as a "cognitive elevation engine, team acceleration base, and resource linkage hub" with a three-tiered training system: "Navigator Class," "Excellence Class," and "Startup Class" [2] - The school plans to launch a "Market Partner Program" to help over 50 companies recruit high-end market talent within three years, addressing the common issue of "heavy R&D, light market" [2] - The goal for the next three years includes training over 500 technology entrepreneurs and helping at least 50 companies achieve annual revenues exceeding 100 million yuan [2] Student Profile and Initial Class - The first cohort of the "Excellence Class" consists of over 30 students from specialized and innovative enterprises, with revenue scales between 100 million and 500 million yuan, indicating they are at a critical stage for scaling [2] - Notable students include Sun Chengliang, Chairman of Wuhan Minsheng, who recently completed a strategic financing round of 688 million yuan [2][3] Personal Insights from Students - Sun Chengliang expressed that as a technology professional, he lacks expertise in management and operations, emphasizing the importance of learning to enhance the company's strategic positioning for greater international market reach [3]

Core Viewpoint - The medical equipment procurement scale is expected to grow rapidly year-on-year due to the implementation of the 2025 equipment renewal policy, with a significant increase in demand for high-end medical devices [1][2][3] Group 1: Equipment Procurement Trends - In December 2025, the procurement scale for new medical devices showed a decline in MR by 11.8%, CT by 7.3%, DR by 3.9%, and ultrasound by 1.3%, while endoscopes increased by 1.4% and surgical robots decreased by 23.9% [1][2] - Cumulatively for the year 2025, the procurement scale for MR increased by 31.4%, CT by 53.2%, DR by 53.2%, ultrasound by 42.3%, endoscopes by 16.3%, and surgical robots by 21.9% [2] Group 2: Company Performance - In December 2025, the performance of specific companies showed that Union Medical's MR declined by 17.4%, while its CT increased by 17.4%. Mindray's ultrasound grew by 13.8%, and KAILI's ultrasound decreased by 13.5%. KAILI's endoscope increased by 61.1%, and Aohua's endoscope grew by 9.4% [2] - For the entire year of 2025, Union Medical's MR grew by 15.6%, CT by 47.7%, Mindray's ultrasound by 56.3%, KAILI's ultrasound by 69.7%, KAILI's endoscope by 85.0%, and Aohua's endoscope by 24.4% [2] Group 3: Policy Impact - The 2024 policy aims to increase medical equipment investment by over 25% compared to 2023 by 2027, enhancing the configuration of high-end equipment to levels seen in middle-income countries [3] - The implementation of the equipment renewal policy is expected to significantly boost procurement levels across various medical institutions, leading to a recovery in the domestic market and a turning point for equipment companies [3]

Core Viewpoint - The medical equipment bidding scale continues to show good growth, driven by the implementation of equipment renewal policies, which is expected to stimulate long-term procurement levels in the medical equipment sector [1][4]. Group 1: Equipment Renewal Policy Impact - The equipment renewal policy is set to be implemented as planned in 2025, with a rapid year-on-year growth in the annual bidding scale for medical equipment. For instance, in December 2025, the bidding scale for MR decreased by 11.8%, while CT and DR saw declines of 7.3% and 3.9%, respectively. However, the overall annual cumulative growth for 2025 shows significant increases: MR grew by 31.4%, CT by 53.2%, DR by 53.2%, ultrasound by 42.3%, endoscopes by 16.3%, and surgical robots by 21.9% [3][4]. - The four ministries jointly issued a notice in 2024, aiming for a more than 25% increase in medical equipment investment by 2027 compared to 2023, enhancing high-end equipment configurations to levels seen in middle-income countries [4]. Group 2: Market Recovery and Company Performance - The domestic market is showing signs of effective recovery due to policy implementation, with medical equipment companies expected to experience a performance turnaround. For example, in the first three quarters of 2025, United Imaging's domestic revenue reached 6.866 billion yuan, reflecting a year-on-year growth of 23.7%, indicating a recovery and structural upgrade trend in the medical equipment industry [4]. - The demand for innovative diagnostic and treatment equipment, particularly in imaging and radiotherapy, is rapidly increasing as a result of the ongoing equipment renewal policies [4].

Group 1 - The core viewpoint is that foreign institutions like Goldman Sachs and UBS are optimistic about the Chinese market, focusing on corporate profit growth as the main driver, replacing valuation recovery, with technology innovation and policy benefits seen as dual engines [1] Group 2 - Strong expectations for profit growth in 2026, with Goldman Sachs predicting a 20% increase in the MSCI China Index and a 12% increase in the CSI 300 Index, with a cumulative rise of 38% from 2026 to 2027, where corporate profits contribute 24% [2] - UBS forecasts a profit growth of over 14% for the MSCI China Index, with overall A-share profit growth rising from 6% in 2025 to 8%, driven by the technology sector, which accounts for 50% of the index [2] - Supporting factors include an increase in nominal GDP growth, a narrowing decline in PPI driving revenue growth, and policies optimizing supply-demand structures in industries like photovoltaics and chemicals [2] Group 3 - The MSCI China Index has a forward P/E ratio of only 12 times, significantly lower than the S&P 500 Index (22 times) and the Indian market (21 times), indicating a historical low [3] - Foreign ownership of A-shares is only 3.68%, much lower than the average of 40% in countries like Japan and South Korea, suggesting substantial room for increased allocation [3] - In the first ten months of 2025, foreign capital inflow into A-shares reached $50.6 billion, more than tripling year-on-year [3] Group 4 - Foreign investment is focusing on technology and structural opportunities, particularly in AI and its supply chain, with key areas including computing infrastructure and application scenarios in fintech and healthcare [4] Group 5 - Beneficiary sectors from policy dividends include new energy companies and high-end manufacturing leaders, with companies like CATL and Ganfeng Lithium receiving upgrades from Morgan Stanley [5] - Companies with high overseas revenue ratios in sectors like new energy vehicles and smart hardware are also targeted [5] - Structural opportunities in consumer services, particularly in dining and prepared foods, may see a rebound in the second half of the year due to PPI recovery [5] Group 6 - In the fourth quarter of 2025, northbound capital is expected to increase holdings in resource stocks while also adding to technology and financial sectors [6]

1月13日，光谷商学院揭牌仪式暨首期"卓越班"开班典礼在武汉举行。华工科技董事长马新强担任院长，蔚来创始人李斌、联影集团薛敏、长江存储董事长 陈南翔等来自新能源汽车、生物医药、集成电路等领域的产业领军人物为学院提供战略指导。 不只是武汉，第一财经记者注意到，国内不少地区都在面向企业家开设商学平台。接受采访的专家表示，地方政府开设企业家商学院，是政府从"管理者"转 向"服务者"的重要体现。 目标3年培育500名科技企业家 叶青在接受第一财经记者采访时提到，光谷商学院还应补齐光谷企业家的两个短板。一是重技术、轻经营的短板，要培养一批"懂技术、懂产业、懂经营、 懂创新"的领军人才，解决科技创业者普遍存在的"技术强、经营弱"的问题。二是"企二代"不够强的短板，光谷企业家也面临着"交班"问题，一些"企二代"在 研究能力、经营能力上还有所欠缺，甚至对接管企业不感兴趣，因此商学院要把培育二代作为重点。 政府为何面向企业家办学 早在2022年8月，河南郑州高新区就在中部地区率先成立企业家学院，通过组织"名企参访-对标学习"等系列活动，开展线上线下相结合、理论实操相结合、 长期短期相结合、请进来走出去相结合、坐下来转起来相结合 ...

Core Insights - The report emphasizes that the Chinese medical device industry is transitioning from rapid domestic growth to a more stable development phase, driven by increasing pressure from medical insurance funding and comprehensive payment reforms. As a result, "going global" has become a strategic necessity for advanced domestic manufacturers [2][3] - The report highlights that the Chinese medical device sector has developed the hard power necessary for global competition, with high-end equipment and high-value consumables rapidly establishing their presence in global supply chains. The increasing share of overseas revenue will become a core indicator of growth and valuation for medical device companies [2][3] Group 1: Market Growth and Strategic Shifts - The medical device market is expected to reach CNY 941.7 billion by 2024 and CNY 1,813.4 billion by 2035, with a CAGR of 6.14% from 2024 to 2035. The global market is projected to grow from USD 623 billion in 2024 to USD 1,157.6 billion by 2035, with a CAGR of 5.80% [17] - Domestic companies are accelerating their international expansion due to internal pressures, including the impact of centralized procurement policies that have significantly reduced prices in the domestic market [21][22] Group 2: International Expansion and Challenges - The report notes that many domestic high-value consumables are gaining FDA and CE certifications, indicating a growing international recognition of Chinese manufacturing capabilities. This trend is particularly evident in Southeast Asia and South America, where companies are gaining experience before tackling more stringent markets like the EU and the US [3][4] - The report discusses various patent disputes faced by Chinese companies during their international expansion, highlighting the challenges of overcoming established international competitors' patent barriers. This includes cases involving major companies like Mindray and Times Angel [27][28] Group 3: Product Categories and Market Dynamics - High-end medical devices, such as imaging equipment and surgical robots, are leading the charge in international markets, with companies like United Imaging and Mindray making significant strides in Europe and the US [3][4] - The report indicates that the demand for high-value consumables is increasing, with companies focusing on innovation and clinical effectiveness to enhance their competitive edge in global markets [4][5] Group 4: Supply Chain and Localization Strategies - The establishment of global marketing networks and supply chain systems is essential for the international success of medical device companies. This includes setting up local subsidiaries, warehouses, and production bases in key markets [3][4] - The report emphasizes the importance of academic promotion and clinical trials in gaining market acceptance, particularly in high-end markets where local healthcare systems may require extensive clinical data for reimbursement [32][33]